COMMUNIQUÉS West-GlobeNewswire

Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
23/07/2026
PITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior to the [...]
Egg Medical annonce une nouvelle ère dans la sécurité en salle de fluoroscopie à la suite d’une déclaration de consensus conjointe
23/07/2026
Tandis que les principales sociétés médicales demandent l’adoption obligatoire de dispositifs de protection contre les rayonnements (ERPD), le système EggNest® Complete s’impose comme la solution définitive de [...]
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), declared in [...]
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
23/07/2026
DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the [...]
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
23/07/2026
Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE ® DLBCL-1 trial and was not met Genmab A/ [...]
HeartSciences Files Its Fiscal 2026 Annual Report on Form 10-K
23/07/2026
Company believes proposed Fortitude merger represents a significant opportunity for the Company’s shareholders; preliminary proxy statement in connection with the Proposed Transaction expected to be filed shortly, with [...]
Abivax renforce ses capacités commerciales avec des nominations stratégiques à des postes clés
23/07/2026
Abivax renforce ses capacités commerciales avec des nominations stratégiques à des postes clés Ces dirigeants expérimentés du secteur apportent plusieurs décennies d’expertise en stratégie commerciale, services aux [...]
Weight Watchers Schedules Second Quarter 2026 Earnings Conference Call
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the second quarter 2026 ended June 30, 2026, after market close on [...]
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
23/07/2026
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Rapid Micro Biosystems to Announce Second Quarter 2026 Financial Results on August 7, 2026
23/07/2026
LEXINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Cytokinetics to Announce Second Quarter Results on August 6, 2026
23/07/2026
SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. [...]
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
23/07/2026
Interim Phase 1 results accepted for poster presentation at ESMO Congress 2026 Achieved pre-specified Stage 1 response threshold in squamous cell carcinoma of the head and neck (SCCHN) cohort and enrolling Stage 2 per [...]
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
23/07/2026
LONDON, July 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 28, 2026 at 8:30 a.m. Eastern [...]
Vaso Corporation Appoints Shaun McMeans to Board of Directors
23/07/2026
PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and [...]
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Report
23/07/2026
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 [...]
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
23/07/2026
BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to [...]
Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026
23/07/2026
SAN FRANCISCO, July 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the [...]
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
23/07/2026
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments Appointed industry leaders bring decades of experience across commercial strategy, patient services, launch readiness, and field force [...]
CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026
23/07/2026
MINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]

Pages